Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An antibody-drug conjugate could be a step toward selective treatment for neuroendocrine prostate cancer.
Antibody-drug conjugates are targeted agents that package cancer drugs for special delivery to tumor cells.
A checkpoint inhibitor combination and an antibody-drug conjugate may offer new treatment options.
The report highlights how cancer research is extending and improving lives and includes a special feature on COVID-19 and cancer challenges.
The antibody-drug conjugate nearly doubled survival time for people with triple-negative breast cancer.
Mylotarg consists of an antibody that binds to the CD33 receptor protein on malignant B cells combined with a chemotherapy drug.
The antibody-drug conjugate is the second drug approved for metastatic breast cancer in the course of a week.
Last year, the FDA approved three new antibody-drug conjugates for treating cancer.
Updated study results show antibody-drug conjugate plus Keytruda shrinks tumors in 73% of patients.
60% of women treated with the antibody-drug conjugate experienced complete or partial tumor shrinkage.
Novel antibody-drug conjugate shrank tumors in more than 40% of people previously treated with immunotherapy.
Antibody-drug conjugate carries a chemotherapy drug directly to cancerous B cells.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.